Precigen Expects Q1 Revenue to Surpass $18 Million Due to Strong Uptake of Recurrent Respiratory Papillomatosis Drug

MT Newswires Live04-07

Precigen (PGEN) said Tuesday it expects Q1 revenue to surpass $18 million due to the strong uptake of Papzimeos, its HPV-specific immunotherapy for the treatment of adults with recurrent respiratory papillomatosis.

The Centers for Medicare & Medicaid Services has also assigned J-code J3404 to the therapy effective April 1, which is set to streamline reimbursement and broaden its access, the company said.

Net product sales for the treatment in Q4 of 2025 were $3.4 million, with Precigen patient hub enrollment exceeding 300 due to physician and patient demand, the company said.

Precigen said it plans to launch a pediatric trial for the drug in Q4, as well as a study to evaluate the potential for redosing patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625693726?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-07 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625693726","market":"hk","top_or_hot":-1,"title":"Precigen Expects Q1 Revenue to Surpass $18 Million Due to Strong Uptake of Recurrent Respiratory Papillomatosis Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> (PGEN) said Tuesday it expects Q1 revenue to surpass $18 million due to the strong uptake of Papzimeos, its HPV-specific immunotherapy for the treatment of adults with recurrent respiratory papillomatosis.</p><p>The Centers for Medicare &amp; Medicaid Services has also assigned J-code J3404 to the therapy effective April 1, which is set to streamline reimbursement and broaden its access, the company said.</p><p>Net product sales for the treatment in Q4 of 2025 were $3.4 million, with Precigen patient hub enrollment exceeding 300 due to physician and patient demand, the company said.</p><p>Precigen said it plans to launch a pediatric trial for the drug in Q4, as well as a study to evaluate the potential for redosing patients.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precigen Expects Q1 Revenue to Surpass $18 Million Due to Strong Uptake of Recurrent Respiratory Papillomatosis Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecigen Expects Q1 Revenue to Surpass $18 Million Due to Strong Uptake of Recurrent Respiratory Papillomatosis Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-07 19:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> (PGEN) said Tuesday it expects Q1 revenue to surpass $18 million due to the strong uptake of Papzimeos, its HPV-specific immunotherapy for the treatment of adults with recurrent respiratory papillomatosis.</p><p>The Centers for Medicare &amp; Medicaid Services has also assigned J-code J3404 to the therapy effective April 1, which is set to streamline reimbursement and broaden its access, the company said.</p><p>Net product sales for the treatment in Q4 of 2025 were $3.4 million, with Precigen patient hub enrollment exceeding 300 due to physician and patient demand, the company said.</p><p>Precigen said it plans to launch a pediatric trial for the drug in Q4, as well as a study to evaluate the potential for redosing patients.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGEN","symbol_name":"Precigen","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2625693726","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625693726","pubTimestamp":1775562366,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Precigen  said Tuesday it expects Q1 revenue to surpass $18 million due to the strong uptake of Papzimeos, its HPV-specific immunotherapy for the treatment of adults with recurrent respiratory papillomatosis.The Centers for Medicare & Medicaid Services has also assigned J-code J3404 to the therapy effective April 1, which is set to streamline reimbursement and broaden its access, the company said.Net product sales for the treatment in Q4 of 2025 were $3.4 million, with Precigen patient hub enrollment exceeding 300 due to physician and patient demand, the company said.Precigen said it plans to launch a pediatric trial for the drug in Q4, as well as a study to evaluate the potential for redosing patients.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PGEN":"Precigen"},"translate_title":"由于复发性呼吸道乳头状瘤病药物的强劲吸收，Precigen预计第一季度收入将超过1800万美元","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGEN":1.5},"content_text":"Precigen (PGEN) said Tuesday it expects Q1 revenue to surpass $18 million due to the strong uptake of Papzimeos, its HPV-specific immunotherapy for the treatment of adults with recurrent respiratory papillomatosis.The Centers for Medicare & Medicaid Services has also assigned J-code J3404 to the therapy effective April 1, which is set to streamline reimbursement and broaden its access, the company said.Net product sales for the treatment in Q4 of 2025 were $3.4 million, with Precigen patient hub enrollment exceeding 300 due to physician and patient demand, the company said.Precigen said it plans to launch a pediatric trial for the drug in Q4, as well as a study to evaluate the potential for redosing patients.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625693726","isCrawlerRequest":true}